ArticleWorld journal of surgical oncology2026
NUF2 interacts with BUB3 and drives lung adenocarcinoma progression through activation of the NF-κB pathway.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundLung adenocarcinoma (LUAD) is the most common form of lung cancer and is often diagnosed at advanced stages. NUF2, a key component of the NDC80 kinetochore complex, is highly expressed in several malignancies, but its function and regulatory mechanism in LUAD remain unclear.
methodsExpression profiling using TCGA, GEO datasets, and LUAD tissue microarrays revealed NUF2 dysregulation in LUAD. Functional assays (CCK-8, EdU, colony formation, Transwell, and xenograft models) were performed to assess the effects of NUF2 gain- or loss-of-function. Protein interactions were examined using immunoprecipitation and mass spectrometry. Transcriptomic sequencing and Western blotting were used to evaluate downstream signaling pathways.
resultsNUF2 expression was significantly elevated in LUAD tissues and cell lines and was positively associated with tumor stage and poor overall survival. NUF2 knockdown inhibited LUAD cell proliferation, migration, and tumor growth, whereas NUF2 overexpression enhanced malignant behaviors. Mechanistically, NUF2 interacted with and stabilized the spindle checkpoint protein BUB3 by preventing proteasomal degradation. Additionally, NUF2 activated the NF-κB signaling pathway, and BUB3 was required for this activation.
conclusionsNUF2 promotes LUAD progression by stabilizing BUB3 and activating NF-κB signaling. Targeting the NUF2–BUB3 axis may represent a novel therapeutic strategy for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.